Evidence map›Paper›PMID 40720044›Full record

ArticleMedical oncology (Northwood, London, England)2025

Annexin A2: regulating glioma's fate and a potential therapeutic target.

Weihai Liu, Xiaofang Zhao, Moksada Regmi, Maksuda Ilyasovna Shamsutdinova, Mukhammadjon Shamsutdinov, Shikun Liu, Yuwei Dai, Yingjie Wang, Hongyi Liu, Jian Wu and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Weihai Liu *State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing, 100191, China.
Xiaofang Zhao *State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing, 100191, China.
Moksada Regmi *State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing, 100191, China.
Maksuda Ilyasovna ShamsutdinovaDepartment of Internal Medicine, Hematology, Transfusiology and Cell Therapy, Termez Branch, Tashkent Medical Academy, Termez, Uzbekistan.
Mukhammadjon ShamsutdinovDepartment of General Surgery, Tashkent Medical Academy Termez Branch, Termez, Uzbekistan.
Shikun LiuState Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing, 100191, China.
Yuwei DaiState Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing, 100191, China.
Yingjie WangState Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing, 100191, China.
Hongyi LiuNational Engineering Research Center for Ophthalmology, Beijing, 100730, China.
Jian WuHenan Academy of Innovations in Medical Science (AIMS), Zhengzhou, 450003, China.
Jun YangState Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing, 100191, China. yangjbysy@bjmu.edu.cn.
Chenlong YangState Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing, 100191, China. vik.yang@pku.edu.cn.
Sino-Uzbek Regenerative Therapy Consortium (SURE)

Funding

AO Spine Research Start-up Grant AOS-Startup-21-016Beijing Nova Program 20230484356Capital Health Research and Development of Special 2022-4-40918National Natural Science Foundation of China 82272675National Natural Science Foundation of China 82371319Peking University Clinical Medicine Plus X-Young Scholars Project PKU2021LCXQ007Peking University Third Hospital Clinical Key Project BYSYZD2021023
6 · The paper itself

Abstract

High recurrence and mortality in glioma are linked to aggressive proliferation. Recent strategies focus on genetic interventions, with Annexin A2 (ANXA2) emerging as a promising target. We wanted to evaluate ANXA2's prognostic value and its role in tumor progression, aiming to establish it as a viable therapeutic target. Bioinformatics analysis of public databases (The Cancer Genome Atlas, Chinese Glioma Genome Atlas, Rembrandt) was performed to validate ANXA2's prognostic significance. Functional assays (on cell lines U87 and U251) and in vivo studies were conducted to examine the impact of ANXA2 on cell proliferation, invasion, apoptosis, cell cycle progression, and tumor volume. Additionally, the relationship between ANXA2 and the Mitogen-Activated Protein Kinase (MAPK) signaling pathway was explored by analyzing key proteins' expression levels and phosphorylation states. Elevated ANXA2 expression correlated with poorer survival rates in glioma, showing variable expression across different grades and subtypes. Silencing ANXA2 impaired glioma cell motility and proliferation, induced apoptosis, altered cell cycle distribution, and reduced tumor volumes in vivo, at least partially through the MAPK pathway. This way, our study validates ANXA2 as a significant prognostic marker for glioma, contributing to tumor progression through the MAPK pathway, underscoring its potential as a therapeutic target.

Indexed as

Annexin A2Brain NeoplasmsGliomaAnimalsApoptosisBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMAP Kinase Signaling SystemMiceMice, NudeAnnexin A2ANXA2 protein, humanBiomarkers, TumorAnnexin A2BiomarkerGliomaMAPKTherapeutic target

Identifiers

PMID40720044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.